QualityStocksNewsBreaks – VolitionRx Limited (NYSE American: VNRX) Reports Breakthrough in Liquid Biopsy With Over 99% Cancer DNA Purity
VolitionRx (NYSE American: VNRX) announced a breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA using its Capture-Seq(TM) platform, overcoming a longstanding challenge of distinguishing cancer DNA from healthy cell-free DNA in blood samples. The company reported strong early validation results, including no false positives and successful detection across initial study cohorts, supporting the potential of the technology as a novel biomarker approach. The company said the advancement could support applications in multi-cancer early detection and minimal residual disease monitoring, representing a combined total addressable market of approximately $36 billion. Volition added that it is…
